BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/9/2021 8:11:25 AM | Browse: 743 | Download: 1437
 |
Received |
|
2020-12-28 01:36 |
|
Peer-Review Started |
|
2020-12-28 01:52 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-01-17 22:51 |
|
Revised |
|
2021-01-28 11:24 |
|
Second Decision |
|
2021-03-03 03:40 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-03-11 03:03 |
|
Articles in Press |
|
2021-03-11 03:03 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-03-22 01:20 |
|
Publish the Manuscript Online |
|
2021-04-09 08:11 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Observational Study |
| Article Title |
Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Taichi Yoshida, Kentaro Takahashi, Kengo Shibuya, Osamu Muto, Yuko Yoshida, Daiki Taguchi, Kazuhiro Shimazu, Koji Fukuda, Fuminori Ono, Kyoko Nomura and Hiroyuki Shibata |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hiroyuki Shibata, MD, PhD, Professor, Department of Clinical Oncology, Akita University Graduate School of Medicine, Hondo 1-1-1, Akita 010-8543, Japan. hiroyuki@med.akita-u.ac.jp |
| Key Words |
Colorectal cancer; Aflibercept; Second-line chemotherapy; Folinic acid-fluorouracil-irinotecan; Palliative chemotherapy; Observational cohort study |
| Core Tip |
We compared the efficacy and safety of aflibercept plus the folinic acid-fluorouracil-irinotecan regimen as salvage treatment with those of second-line treatment in patients with advanced colorectal cancer. In the second-line and salvage therapy settings, the objective response rates were 11% and 0%, respectively (P = 0.50). The disease control rates, times to aflibercept treatment failure, median survival times post-aflibercept, and incidences of adverse effects greater than or equal to grade 3 were similar in the two groups. Aflibercept could be safe and confer a survival benefit in patients with advanced colorectal cancer, regardless of the number of treatment lines. |
| Publish Date |
2021-04-09 08:11 |
| Citation |
Yoshida T, Takahashi K, Shibuya K, Muto O, Yoshida Y, Taguchi D, Shimazu K, Fukuda K, Ono F, Nomura K, Shibata H. Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture. World J Gastrointest Oncol 2021; 13(4): 295-304 |
| URL |
https://www.wjgnet.com/1948-5204/full/v13/i4/295.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v13.i4.295 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
